Shares in Oxford Biomedica shares rose 6% today after it reported half-year results. The listed cell and gene therapy pioneer, which is targeting profitability, reiterated previous full-year guidance as it reported a 9% increase in revenues to £79.8 million for the six months ended 30th June 2026. With 17 new clients signed in H1 2026 … Continue reading Oxford Biomedica shares rise as it targets profitability